Krispy Kreme, Inc. SEC Filings

Krispy Kreme, Inc. (DNUT) Form 4: Chief Accounting Officer Kelly P. McBride was granted 62,696 restricted stock units (RSUs) on 07/01/2025 at an acquisition price of $0. Following the award, McBride’s direct beneficial ownership rises to 149,147 shares, comprising 9,251 common shares and 139,896 unvested RSUs.

The RSUs vest 60 % on 07/01/2026 and 40 % on 07/01/2027, settling one-for-one into common stock upon vesting. No sales, option exercises, or other derivative transactions were reported. The filing represents routine equity compensation designed to align management incentives with long-term shareholder value and does not, on its own, signal a change in the company’s financial outlook.

GT Biopharma, Inc. (Nasdaq: GTBP) has filed a Rule 424(b)(3) resale prospectus covering up to 54,423,826 shares of common stock—>17x the current float of 3.15 million shares. The shares may be sold from time to time by existing investors and consist of:

• 14.56 million shares issuable on conversion of 6,612 shares of Series L 10% Convertible Preferred Stock issued in a May 2025 private placement.
• 14.56 million shares issuable upon exercise of common warrants issued in the same placement (exercise price $2.043).
• 300,000 commitment shares tied to a $20 million Committed Equity Facility (CEF).
• Up to 25 million shares the company may issue to 5 Narrow Lane, L.P. and Hailstone Peak Funding, LLC under the CEF at 93% of the VWAP.

The company will not receive proceeds from the resale of these shares. It could, however, raise: (i) $5.95 million already received from the private placement; (ii) up to $20 million from future CEF draws; and (iii) cash from warrant exercises. Use of proceeds is earmarked for general working capital.

Key financing terms

• CEF may be tapped at GTBP’s discretion over 36 months, subject to a 25 million share exchange cap and 4.99%/9.99% ownership blockers.
• Purchase price equals 93% of the day’s VWAP, creating an effective 7% discount and potential downward pressure on the stock.
• Series L preferred carries a 10% cash/stock dividend (12% after one year) and converts at $2.043, subject to anti-dilution adjustments.

Capital structure & dilution

• Outstanding common shares: 3,147,995.
• Warrants outstanding: 16,751,669 (avg. strike $3.07); options: 124,600 (avg. strike $32.69).
• If all 54.4 million shares are issued, existing holders would own roughly 5.5% of the post-offering shares.

Operational & risk highlights

• GTBP is a clinical-stage biotech developing TriKE® NK-cell engagers for cancer. No commercial revenue disclosed in this filing.
• Going-concern uncertainty: management warns current cash is insufficient to fund operations for 12 months without new financing.
• Nasdaq compliance: Equity deficiency notice received Nov 2024; compliance was regained on 13 Jun 2025 but will continue to be monitored.
• Stock closed at $3.09 on 2 Jul 2025; historically trades below $5, qualifying as a penny stock with attendant trading restrictions.

Investors face substantial dilution risk, dependence on external capital, preferred-stock overhang, and continuing listing uncertainty, offset by the cash flexibility provided by the CEF and recent private placement.

JPMorgan Chase Financial Company LLC, guaranteed by JPMorgan Chase & Co., is offering 12-month Capped Buffered Return Enhanced Notes linked to the S&P 500 Index (SPX). Investors will pay a $1,000 minimum denomination and receive at maturity: (i) 2.0× any positive Index return, subject to a Maximum Return of at least 10.20%; (ii) full principal back if the Index closes up to 15% below its initial level; or (iii) a loss of 1% of principal for every 1% decline beyond the 15% buffer. Key dates include a 27 Jun 2025 observation date and a 9 Jul 2026 maturity. The preliminary estimated value is not less than $970 per $1,000 note, indicating an initial issue premium. The notes pay no coupons, dividends or voting rights and are exposed to the credit risk of both issuing entities. Liquidity is expected to be limited, valuations can fall below par before maturity, and conflicts may arise because JPMorgan acts as both issuer and calculation agent. Tax treatment is uncertain and investors are urged to consult advisers. Overall, the instrument suits investors seeking buffered, short-term SPX exposure with capped upside and willing to accept credit and liquidity risk.

Krispy Kreme (NASDAQ: DNUT) announced the termination of its strategic partnership with McDonald's USA, effective July 2, 2025. The decision was mutually agreed upon by both companies, ending their Business Relationship Agreement that was originally established on March 22, 2024.

Key details of the termination include:

• Both companies issued a joint press release on June 24, 2025
• A formal Business Relationship Termination Agreement was signed on June 23, 2025
• Post-termination, certain obligations will survive, including confidentiality and indemnification provisions
• All other mutual obligations under the original agreement will cease on the Termination Effective Date

This material event was disclosed through an 8-K filing signed by CEO Joshua Charlesworth. The filing includes exhibits of the press release (99.1) and Cover Page Interactive Data File in Inline XBRL format.

Krispy Kreme Chief Accounting Officer Kelly P. McBride reported a Form 4 filing on June 28, 2025, disclosing transactions from June 20, 2025. The key details include:

• McBride surrendered 4,767 shares of common stock at $2.67 per share to cover tax withholding obligations related to the vesting of restricted stock units (RSUs)
• Following the transaction, McBride beneficially owns 86,451 shares, consisting of: - 9,251 direct shares - 77,200 unvested RSUs
• The transaction was coded as 'F' (Payment of exercise price or tax liability using portion of securities received)

This routine transaction represents standard tax withholding practices for executive equity compensation and does not indicate a discretionary sale by the insider.

Krispy Kreme director Gordon von Bretten received a significant equity grant on June 17, 2025, consisting of 47,795 restricted stock units (RSUs). The RSUs were granted at $0 cost and will vest on June 17, 2028, representing a three-year vesting schedule.

Key details of the transaction:

• Transaction Type: Acquisition of non-derivative securities (RSUs)
• Ownership: Direct ownership
• Settlement Terms: One-for-one basis in common stock upon vesting
• Total Holdings: 47,795 unvested RSUs following the transaction

This equity grant aligns the director's interests with shareholders through a long-term vesting period, demonstrating Krispy Kreme's commitment to performance-based compensation and retention of key board members.

Krispy Kreme director Easwaran Sundaram received a significant equity grant on June 17, 2025, as reported in this Form 4 filing. The transaction details reveal:

• Acquired 47,795 restricted stock units (RSUs) at $0 cost basis
• RSUs will vest on June 17, 2028 (3-year vesting period)
• Upon vesting, RSUs convert to common stock on a one-for-one basis
• All securities are held in direct ownership

This equity grant appears to be part of director compensation and represents a significant long-term alignment between the director and shareholder interests. The three-year vesting period serves as a retention mechanism while incentivizing long-term value creation.

Krispy Kreme director Gerhard W. Pleuhs received a significant equity grant on June 17, 2025, as reported in this Form 4 filing. The transaction details reveal:

• Acquisition of 47,795 restricted stock units (RSUs) at $0 cost
• RSUs will vest on June 17, 2028 (3-year vesting period)
• Upon vesting, RSUs convert to common stock on a one-for-one basis
• Following the transaction, Pleuhs holds a total of 68,399 unvested RSUs

This equity grant appears to be part of the company's director compensation program, aligning the director's interests with shareholders through long-term stock ownership. The transaction was reported within the required timeframe and executed through a power of attorney.

Krispy Kreme Director Bernardo Hees reported significant insider transactions on Form 4, filed June 28, 2025, detailing changes in beneficial ownership:

• Acquired 47,795 Restricted Stock Units (RSUs) on June 17, 2025, at $0 cost
• RSUs will vest on June 17, 2028 and convert to common stock on a one-for-one basis
• Currently holds 665,110 shares directly, including: - 617,315 direct shares - 47,795 unvested RSUs
• Indirectly owns 694,445 shares through BHBK LLC, over which he exercises sole investment power

This equity-based compensation grant aligns the director's interests with shareholders through a three-year vesting period, representing a significant long-term commitment to the company.